Catalent Joins Civica’s New Business Arm For Generic Manufacturing
Civica Struck Deal with Blue Cross Blue Shield Association Last Year
CDMO Catalent and US health insurance giant Anthem have joined up with non-profit Civica’s new outpatient-focused generics business arm, CivicaScript, with plans to begin rolling out products as early as next year.
You may also be interested in...
Civica has announced a further $27.8m investment to support its plans for insulin and other essential medicines. The news comes shortly after CivicaScript announced its first launch in the form of abiraterone tablets.
Civica Rx’s chief operating officer Ned McCoy is to step up as CEO, ahead of the company’s landmark manufacturing facility commencing operations in early 2024.
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.